

1. Record Nr.	UNINA9910495184503321
Titolo	Advances in glycobotechnology // edited by Erdmann Rapp and Udo Reichl
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-69590-5
Descrizione fisica	1 online resource (467 pages)
Collana	Advances in Biochemical Engineering/Biotechnology ; ; v.175
Disciplina	572.68
Soggetti	Glycoproteins - Biotechnology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Preface -- Contents -- Animal Cell Expression Systems -- 1 Introduction -- 2 Production of Glycosylated Proteins for Therapeutic Use -- 2.1 Process Variables -- 2.2 Culture Media: The Contribution of Nutrients to Glycosylation -- 2.3 Galactosylation -- 2.4 Sialylation -- 2.5 Ammonia -- 2.6 pH Value -- 2.7 Oxygen -- 2.8 Use of Inhibitors to Control Glycosylation -- 2.9 Predictive Metabolic Models of Glycosylation -- 3 Production of Cell Culture-Derived Viral Antigens -- 3.1 Impact of Cultivation Conditions on Glycosylation of Hemagglutinin of Influenza A Virus -- 3.2 Influenza A Virus Hemagglutinin -- 3.3 Impact of Host Cells on the Hemagglutinin Glycosylation Pattern -- 3.4 Impact of Virus Strains on the Hemagglutinin Glycosylation Pattern -- 3.5 Impact of Cultivation Vessels and Process Parameters on the Hemagglutinin Glycosylation Pattern -- 4 Conclusions -- References -- Glycoengineering of Mammalian Expression Systems on a Cellular Level -- 1 Introduction -- 1.1 Glycosylation -- 1.2 Sialylation -- 1.3 Fucosylation -- 2 Technologies for Glycoengineering Through Gene Knocking Down, In, and Out -- 2.1 siRNA -- 2.2 shRNA -- 2.3 Random Mutagenesis and Homologous Recombination Knockout Selection -- 2.4 ZFNs -- 2.5 TALENs -- 2.6 CRISPR/Cas9 -- 3 CHO Glycoengineering -- 3.1 Overexpression of GnT Genes -- 3.2 Overexpression of Sialyltransferase and Galactosyltransferase Genes -- 3.3 Inhibition of Sialidase Activity -- 4 CHO Glycoproteomics and Combined `Omics` -- 4.1 Glycoproteomics -- 4.2 Combined `Omics`

-- 5 Conclusions and Outlook -- References -- Glycobiotechnology of the Insect Cell-Baculovirus Expression System -- 1 Insect Glycobiology -- 2 Effect of Bioprocessing Conditions on the Glycosylation Profile of Proteins Produced by Insect Cells -- 3 Glycoengineering of Insect Cells. 4 Impact of Glycosylation on Proteins and Products Produced by Insect Cells -- 5 Conclusions and Outlook -- References -- Engineering of Yeast Glycoprotein Expression -- 1 Introduction -- 1.1 Rationale for Using Yeast in Protein Expression -- 1.2 *Saccharomyces cerevisiae* Versus *Pichia pastoris* -- 2 N-Glycosylation in Yeast -- 2.1 Engineering N-Glycosylation in Yeast -- 2.1.1 Approach 1: Elimination of Yeast Glycosyltransferases -- 2.1.2 Approach 2: Interference in Lipid-Linked Oligosaccharide Assembly -- 2.1.3 Approach 3: Overexpression of Endo--N-Acetylglucosaminidases -- 3 -Mannose Depletion -- 4 O-Glycosylation in Yeast -- 4.1 Reducing or Removing O-Glycans in Yeast -- 4.1.1 Making Pmt Knockouts -- 4.1.2 PMT Inhibitors -- 4.1.3 Expression of Mannosidases to Limit O-Mannose Chain Length -- - 1,2-Mannosidase -- Lysosomal Mannosidases -- Other Lysosomal Mannosidases -- 4.2 Humanization of O-Glycans in Yeast -- 4.2.1 Mucin Type -- 4.2.2 -Dystroglycan-Type O-Glycans -- 4.2.3 O-Fucosylation -- 5 Filamentous Fungi -- 6 Examples of Recombinant Proteins Expressed in Glyco-Engineered Yeast Strains: Glycosylation Considerations -- 6.1 Production of Monoclonal Antibodies -- 6.2 Enzyme Replacement Therapies -- 6.3 Vaccines -- 6.4 Other Therapeutic Proteins -- 7 Future Prospects -- 7.1 Genome Engineering in Yeast -- 8 Conclusion -- References -- Glyco-Engineering of Plant-Based Expression Systems -- 1 Introduction -- 2 Endogenous Glycosylation Pathways in Plants -- 2.1 N-Linked Glycosylation in Plants -- 2.2 O-Linked Glycosylation in Plants -- 3 N-Linked Glycosylation of Recombinant Proteins in Plants Without Glyco-Engineering -- 3.1 Species-Dependent and Tissue-Dependent Effects -- 4 The Impact of Protein Targeting on N-Linked Glycosylation -- 4.1 Secreted Proteins and the Role of the ER and Golgi Apparatus -- 4.2 Proteins Retained in the ER. 4.3 Formation of ER-Derived Compartments -- 4.4 Proteins Targeted to the Vacuole -- 4.5 Proteins Targeted to Other Compartments -- 5 O-Linked Glycosylation of Recombinant Proteins in Plants Without Glyco-Engineering -- 6 Glyco-Engineering in Plants -- 6.1 Glyco-Engineering Strategies -- 6.2 Elimination of Plant N-Linked Glycans -- 6.3 Introduction of Human N-Linked Glycans -- 6.3.1 Core (1,6) Fucose -- 6.3.2 Multi-Antennary Complex Glycans and Bisecting GlcNAc Residues -- 6.3.3 Glycans Containing (1,4)Galactose -- 6.3.4 Terminal Sialylation and the LewisX Epitope -- 6.4 Engineering of O-Linked Glycans -- 6.5 Exploiting Plant Glycosylation for Selective Product Purification -- 7 Conclusions -- References -- Bacterial Glycoengineering as a Biosynthetic Route to Customized Glycomolecules -- 1 Bacteria as a Platform for Polysaccharide and Glycoconjugate Production -- 2 Polysaccharide Production in Bacteria -- 3 Bioengineering of Secreted Oligosaccharides in Bacteria -- 4 Bioengineering of Exopolysaccharides in Bacteria -- 5 Bioengineering of Intracellular and Cell-Associated Polysaccharides in Bacteria -- 6 Bioengineering of Eukaryotic Polysaccharides on the LPS Core in Bacteria -- 7 Bioengineering of Eukaryotic Polysaccharides on the Lipid Anchor Und-PP in Bacteria -- 8 Glycoprotein Expression in Bacterial Hosts: Current Applications and Future Opportunities -- 9 N-Linked Glycoprotein Expression in Bacteria -- 10 Customized N-Glycoproteins Produced Recombinantly in *E. coli* -- 11 Expanding Glycosylation Through Identification of Alternative Oligosaccharyltransferases -- 12 Alternative Routes for Bacterial Protein N-Linked Glycosylation -- 13

Customized O-Glycoproteins Produced Recombinantly in *E. coli* -- 14
Alternative Routes for Bacterial Protein O-Linked Glycosylation -- 15
Alternative Therapeutic Bacterial Conjugates.
16 Concluding Remarks and Outlook -- References -- Advances in the
Chemical Synthesis of Carbohydrates and Glycoconjugates -- 1
Chemical Synthesis of Oligosaccharides -- 2 Synthesis of Building
Blocks -- 2.1 Glycosylation Reactions and Stereoselectivity -- 3
Assembly of Oligosaccharides -- 4 Solution-Phase Synthesis of Glycans
-- 4.1 Modification of Glycans -- 4.2 Removal of the Protecting
Groups, Final Deprotection -- 4.3 Solid-Phase Synthesis of
Oligosaccharides -- 4.4 Automated Assembly of Oligosaccharides -- 5
Synthesis of Glycoconjugates -- 5.1 Synthesis of Neoglycoconjugates
-- 5.2 Synthesis of Natural Glycoconjugates -- 6 Glycolipids and
Amphiphilic Glycoconjugates -- 7 Conclusions and Outlook --
References -- Enzymatic Synthesis of Glycans and Glycoconjugates -- 1
Introduction -- 2 Glycan Synthesis with Leloir Glycosyltransferase --
2.1 The Choice of Leloir Glycosyltransferases -- 2.2 Nucleotide Sugars
-- 2.2.1 Biosynthesis of Nucleotide Sugars -- 2.2.2 Synthesis of
Nucleotide Sugars -- 2.2.3 Production of Nucleotide Sugars -- 2.2.4 In
Situ Regeneration of Nucleotides and Nucleotide Sugars -- 3 Practical
Application of Enzymatic Glycosylation Reactions -- 3.1
Glycosaminoglycans: Hyaluronic Acid, Heparan Sulfate, Heparin,
Chondroitin Sulfate, Dermatan Sulfate -- 3.1.1 Structure and Synthesis
of GAGs -- 3.1.2 Biology of GAGs -- 3.1.3 Biomedical Application of
GAGs -- 3.1.4 Industrial Production of GAGs -- 3.2 Enzymatic
Synthesis of Human Milk Oligosaccharides -- 3.3 Microreactors for
Automated Enzymatic Glycan Synthesis -- 3.4 Glycoconjugate Vaccines
-- 3.5 In Vitro Glycoengineering of Pharma Glycoproteins -- References
-- Recombinant Proteins and Monoclonal Antibodies -- 1 Introduction
-- 2 Impact of Glycosylation on Structure and Function -- 3 Humoral
Immune Response and Recombinant Antibody Therapeutics.
4 Polypeptide Structure of Human IgG -- 5 IgG Subclasses -- 6
Antigens -- 7 IgG-Fc Glycosylation Is Essential for Effector Function
Activation -- 8 Glycosylation of IgG-Fc, Derived from Polyclonal Human
Serum IgG -- 9 IgG-Fc Glycoform Profiles of Recombinant IgG Antibody
Therapeutics -- 10 Impact of IgG-Fc Glycoform on Downstream
Effector Functions -- 10.1 Influence of Fucose and Bisecting N-
Acetylglucosamine on IgG-Fc Activity -- 10.2 Influence of
Galactosylation on IgG-Fc Activity -- 10.3 Sialylation of IgG-Fc
Oligosaccharides -- 11 Recombinant Glycoproteins Bearing High
Mannose Oligosaccharides -- 12 IgG-Fc Glycoform-Ligand
Interactions: An Attempt to Rationalize -- 13 IgG-Fab Glycosylation --
14 Concluding Remarks -- References -- Impact of Protein
Glycosylation on the Design of Viral Vaccines -- 1 Introduction -- 2
Protein N- and O-Glycosylation -- 2.1 Biosynthesis of N-Glycans in
Mammals -- 2.2 Biosynthesis of N-Glycans in Insects -- 2.3
Biosynthesis of O-Glycans -- 3 Viral Glycosylation -- 3.1 Viral Glycans
in the Replication of Enveloped Viruses -- 3.1.1 Virus Binding and Cell
Entry -- 3.1.2 Virus Assembly and Release -- 3.2 Viral Glycans in
Immune Evasion -- 3.2.1 Glycan Shielding -- 3.2.2 Secreted
Glycoproteins -- 4 Viral Vaccine Design -- 4.1 Live-Attenuated
Vaccines -- 4.2 Inactivated Vaccines -- 4.3 Subunit Vaccines -- 4.4
Influenza Virus: A Representative Example of the Importance of
Glycosylation -- 5 Novel Glycan-Exploiting Vaccine Strategies -- 5.1
Sialylated Glycans with N-Glycolylneuraminic Acid -- 5.2 The -Gal
Epitope -- 5.3 Targeting CLRs: Mannose-Rich and Other Fungal
Glycans -- 5.4 Insect-Produced Glycans -- 5.5 Plant-Produced Glycans
-- 6 Perspectives -- References -- Interplay of Carbohydrate and

Carrier in Antibacterial Glycoconjugate Vaccines -- 1 Combating
Bacterial Disease with Advances in Glycobiotechnology.
2 Unconjugated Polysaccharide Vaccines.
